Calcitonin Gene-Related Peptide Receptors and the Prevention of Migraines
Migraines are the third most prevalent disease in the world affecting approximately 15% of the population, or over one billion people. Each year, employers lose greater than $13 billion due to 113 million missed work days due to migraine. A great cost-burden and high incidence rate show a continued need for migraine treatment options. In choosing a treatment for a migraine attack, quick onset of action is one of the most important qualities. Common choices include the triptan class, NSAIDs, and a combination of aspirin, caffeine, and acetaminophen. In addition, there has been increased research into calcitonin gene-related peptides (CGRP). Due to side effect profiles, the monoclonal antibodies have been more successful than the antagonists studied. Monoclonal antibodies alone, though, have not completely eradicated migraine days per month and more research is needed.